The CDC and Academy of Pediatrics (AAP) recommend nirsevimab or clesrovimab for prophylaxis of severe RSV disease in infants and young children whose mothers did not receive RSV vaccines during weeks 32 to 36 of pregnancy and at least 14 days prior to delivery.
Nirsevimab (Beyfortus) – FAQs for Healthcare Professionals
Published December 11, 2025
